第四届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）第四届董事会 第十八次会议于 2025 年 11 月 14 日在公司会议室以现场结合通讯的方式召开。 因时间紧迫，全体董事一致同意豁免会议通知时间要求。本次会议应出席董事 9 人，实际出席董事 9 人。本次会议由董事长王毅清先生召集并主持，公司高级管 理人员列席了本次会议。会议的召集、召开和表决程序符合有关法律、法规、规 章和《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，形成如下决议： （一）审议通过《关于续聘会计师事务所的议案》 董事会同意续聘天健会计师事务所（特殊普通合伙）为公司 2025 年度审计 机构，聘期一年。 证券代码：301126 证券简称：达嘉维康 公告编号：2025-073 湖南达嘉维康医药产业股份有限公司 1 （二）审议通过《关于召开 2025 年第四次临时股东会的议案》 公司拟于 2025 年 12 月 1 日召开公司 2025 年第四次临时股东会。 表决结果：9 ...

关于湖南达嘉维康医药产业股份有限公司 2025年第三次临时股东会的 湖南启元律师事务所 （一）本所律师出具本法律意见书是基于公司已承诺所有提供给本所律师的 文件的正本以及经本所律师查验与正本保持一致的副本均为真实、完整、可靠， 无隐瞒、虚假或重大遗漏之处。 （二）本所律师遵循了勤勉尽责和诚实信用原则，严格履行了法定职责，对 本法律意见书出具日以前已经发生或者存在的事实进行了充分的核查验证，保证 本法律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误导性陈述或者重大遗漏。 湖南启元律师事务所（以下简称"本所"）接受湖南达嘉维康医药产业股份 有限公司（以下简称"公司"）的委托，指派本所律师出席了公司 2025 年第三次 临时股东会（以下简称"本次股东会"），对本次股东会的召集和召开程序、出 席会议人员及召集人的资格、表决程序和表决结果的合法有效性进行律师见证， 并发表本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等我国现行法律、法规、规范 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2025-072 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、会议召开的日期、时间 （1）现场会议召开时间：2025 年 11 月 13 日（星期四）14:30 （2）网络投票时间：2025 年 11 月 13 日（星期四） 湖南达嘉维康医药产业股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决议案的情形。 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 11 月 13 日 9:15-9:25、9:30-11:30，13:00-15:00；通过深圳交易所互联网投票系统 投票的具体时间为：2025 年 11 月 13 日 9:15—15:00 期间的任意时间。 2、会议地点：湖南省长沙市岳麓区茯苓路 30 号湖南达嘉维康医药产业股份 有限公司三楼会议室 3、召开方式：本次会议采用现场投票和网络投票相结合的方式召开 4、召集人：公司董事会 5、主持人：董事长王毅清先生 ...

Core Insights - The three major stock indices experienced a slight decline on November 12, with the pharmaceutical sector showing strength, particularly with stocks like Yaoyigou hitting the daily limit and Jianfa Zhixin rising over 10% [2] Industry Summary - The National Disease Control and Prevention Administration held a press conference on November 10 regarding the prevention and control of acute respiratory infectious diseases during the autumn and winter seasons. Monitoring data indicates that flu activity in China is currently on the rise, with the H3N2 subtype accounting for over 95% of cases [2] - The China Securities Journal reports that the trend of innovation going global is clear, with the pharmaceutical sector leading the way. The ongoing reform in drug review processes is yielding benefits, and the Chinese innovative drug industry has entered a 2.0 era, shifting from "import imitation" to "innovation output" [2] - The report highlights that the development of innovative drugs is supported by improved investment and financing data, indicating a new cycle for CXO and upstream sectors. The potential for medical devices and other categories to also expand internationally is promising [2]

Core Viewpoint - The pharmaceutical commercial sector experienced a significant surge, with the sector index reaching a new high for the year [1]. Group 1: Market Performance - Individual stocks such as YaoYigou saw a rapid increase, hitting a 20% limit up within approximately 4 minutes of opening [3]. - HeFu China achieved a limit up after a strong opening, marking 11 limit ups in the last 12 trading days [3]. - RenMin TongTai opened with a limit up, achieving three consecutive limit ups [3]. Group 2: Stock Details - YaoYigou: +19.99%, previous amount 3.75 billion, current market cap 33.59 billion, current price 35.14 [4]. - JianFa ZhiXin: +14.86%, previous amount 9.66 billion, current market cap 154.01 billion, current price 36.55 [4]. - RenMin JianTan: +10.04%, previous amount 59.297 million, current market cap 72.49 billion, current price 12.50 [4]. - HeLiang China: +10.02%, previous amount 12.16 billion, current market cap 79.97 billion, current price 20.09 [4]. - DaShenLin: +4.67%, previous amount 3.23 billion, current market cap 222.1 billion, current price 19.50 [4]. - YiFeng Pharmacy: +2.80%, previous amount 3.71 billion, current market cap 303.0 billion, current price 24.99 [4].

Core Viewpoint - The A-share market is seeing active trading in flu-related stocks, driven by an early peak in respiratory syncytial virus (RSV) and flu activity in China, as reported by the National Disease Control [1][2]. Group 1: Market Activity - Aipeng Medical has risen over 10%, while Panlong Pharmaceutical has reached a 10% limit up, with other companies like Rejing Bio and Dongfang Bio also seeing significant gains [1]. - The latest flu monitoring report indicates an increase in flu activity in southern provinces and a rise in northern provinces during the 44th week of 2025 [1]. Group 2: Key Data on Stocks - Aipeng Medical (300753) has a market cap of 3.969 billion and a year-to-date increase of 79.09% [2]. - Panlong Pharmaceutical (002864) has a market cap of 3.788 billion and a year-to-date increase of 18.84% [2]. - Rejing Bio (688068) has a market cap of 14 billion and a year-to-date increase of 144.44% [2]. - Dongfang Bio (688298) has a market cap of 5.836 billion with a slight year-to-date decrease of 1.30% [2]. - Other notable stocks include Te Yi Pharmaceutical (002728) with a market cap of 6.961 billion and a year-to-date increase of 52.45% [2].

Core Insights - On November 10, Dajia Weikang's stock rose by 1.70%, with a trading volume of 58.99 million yuan [1] - The company reported a financing buy-in of 10.40 million yuan and a net financing buy-in of 6.02 million yuan on the same day [1] - As of November 10, the total financing and securities lending balance for Dajia Weikang was 70.35 million yuan, indicating a high level of financing activity [1] Financing Summary - On November 10, Dajia Weikang had a financing buy-in of 10.40 million yuan, with a current financing balance of 70.35 million yuan, accounting for 2.73% of its market capitalization [1] - The financing balance is above the 50th percentile level over the past year, indicating a relatively high position [1] Securities Lending Summary - On November 10, there were no shares repaid or sold in securities lending, with a remaining quantity of 100 shares and a securities lending balance of 1,254 yuan, which is above the 80th percentile level over the past year [1] Company Performance - As of October 31, Dajia Weikang had 15,900 shareholders, a decrease of 2.91% from the previous period, with an average of 8,659 circulating shares per shareholder, an increase of 3.00% [2] - For the period from January to September 2025, Dajia Weikang achieved operating revenue of 4.13 billion yuan, a year-on-year increase of 3.69%, while the net profit attributable to shareholders decreased by 86.02% to 5.10 million yuan [2] Dividend Information - Since its A-share listing, Dajia Weikang has distributed a total of 38.07 million yuan in dividends, with 31.05 million yuan distributed over the past three years [3] - Notably, as of September 30, 2025, the fund "Noan Multi-Strategy Mixed A" (320016) has exited the list of the top ten circulating shareholders [3]

Core Insights - On November 6, Dajia Weikang's stock fell by 0.57%, with a trading volume of 40.65 million yuan [1] - As of November 6, the company had a total margin balance of 63.65 million yuan, with a net margin purchase of 1.30 million yuan on that day [1][2] - For the period from January to September 2025, Dajia Weikang reported a revenue of 4.13 billion yuan, a year-on-year increase of 3.69%, while net profit decreased by 86.02% to 5.10 million yuan [2] Financing and Margin Trading - On November 6, Dajia Weikang had a financing buy amount of 3.66 million yuan and a financing repayment of 2.36 million yuan, resulting in a net financing purchase of 1.30 million yuan [1] - The current financing balance of 63.65 million yuan accounts for 2.52% of the circulating market value, which is below the 40th percentile level over the past year, indicating a low position [1] - The company had no short selling on November 6, with a short selling balance of 1,229 yuan, which is above the 80th percentile level over the past year, indicating a high position [1] Shareholder and Dividend Information - As of October 31, the number of Dajia Weikang shareholders was 15,900, a decrease of 2.91% from the previous period, while the average circulating shares per person increased by 3.00% to 8,659 shares [2] - Since its A-share listing, Dajia Weikang has distributed a total of 38.07 million yuan in dividends, with 31.05 million yuan distributed in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders of Dajia Weikang saw the exit of the Noan Multi-Strategy Mixed A fund from the list [3]

Core Viewpoint - Dajia Weikang (301126) responded to investor inquiries on November 6, indicating that the number of shareholders as of October 31, 2025, can be found in previously disclosed information [1] Summary by Categories - Company Information - Dajia Weikang has provided information regarding its shareholder count as of a future date, October 31, 2025 [1]

Core Viewpoint - The company, Dajiahui Kang, has provided information regarding the distribution of its subsidiaries' pharmacies in Hainan province, specifically in cities such as Haikou, Wenchang, Qionghai, and Ding'an [1] Company Summary - Dajiahui Kang operates two main subsidiaries: Hainan Dajiahui Kang Pharmacy Chain Co., Ltd. and Hainan Dajiahui Kang Hongchuntang Pharmacy Chain Co., Ltd. [1] - The pharmacies are primarily located in Haikou, Wenchang, Qionghai, and Ding'an, indicating a focused regional presence in Hainan [1]